Kim Eun Key, Hong Joon Pio
Seoul, Korea From the Department of Plastic and Reconstructive Surgery, University of Ulsan College of Medicine, Asan Medical Center.
Plast Reconstr Surg. 2007 Dec;120(7):1774-1781. doi: 10.1097/01.prs.0000287131.53488.c4.
Erythropoietin is traditionally known to regulate erythropoiesis, but recently its protective effect against ischemia-reperfusion injury has been studied in cardiovascular and neuronal systems. This study investigated the effect of recombinant human erythropoietin on ischemia-reperfusion injury in a rat transverse rectus abdominis musculocutaneous (TRAM) flap model.
Twenty-four Sprague-Dawley rats were divided into a control group (n = 12) and a group treated with erythropoietin (n = 12). A superiorly based TRAM flap was elevated and ischemic insult was given for 4 hours. Thirty minutes before reperfusion, single-dose recombinant human erythropoietin (5000 IU/kg) was injected through the intraperitoneal route in the treatment group. At 24 hours postoperatively, systemic neutrophil count, tissue myeloperoxidase activity, amount of malondialdehyde, nitric oxide content, tissue water content, and histologic finding of inflammation were evaluated. At day 10 postoperatively, flap survival rate, angiogenesis, and change in hematocrit level were evaluated.
The myeloperoxidase activity and tissue water content were significantly lower (p < 0.01 and p < 0.005, respectively), and the tissue nitric oxide level was significantly higher (p < 0.005) in the treatment group 24 hours after reperfusion. Perivascular neutrophil infiltration and intravascular adhesion were marked in the control group. Mean flap survival after 10 days was 69 percent in the treatment group and 47 percent in the control group, demonstrating a significant difference (p < 0.005). Neovascularization in the treatment group was also greater than that in the control group. No significant hematocrit rise was noted 10 days after erythropoietin administration.
Recombinant human erythropoietin improved flap survival in ischemia-reperfusion-injured rat TRAM flaps by the possible mechanism of suppressed inflammation, decreased infiltration of neutrophils, increased nitric oxide, and enhanced angiogenesis.
传统上已知促红细胞生成素可调节红细胞生成,但最近其对缺血 - 再灌注损伤的保护作用已在心血管和神经系统中得到研究。本研究在大鼠腹直肌横行肌皮瓣(TRAM瓣)模型中研究重组人促红细胞生成素对缺血 - 再灌注损伤的影响。
将24只Sprague - Dawley大鼠分为对照组(n = 12)和促红细胞生成素治疗组(n = 12)。掀起一个以头侧为蒂的TRAM瓣并给予4小时的缺血损伤。在再灌注前30分钟,治疗组通过腹腔途径注射单剂量重组人促红细胞生成素(5000 IU/kg)。术后24小时,评估全身中性粒细胞计数、组织髓过氧化物酶活性、丙二醛含量、一氧化氮含量、组织含水量以及炎症的组织学表现。术后第10天,评估皮瓣存活率、血管生成以及血细胞比容水平的变化。
再灌注后24小时,治疗组的髓过氧化物酶活性和组织含水量显著降低(分别为p < 0.01和p < 0.005),而组织一氧化氮水平显著升高(p < 0.005)。对照组可见血管周围中性粒细胞浸润和血管内黏附明显。治疗组10天后皮瓣平均存活率为69%,对照组为47%,差异有统计学意义(p < 0.005)。治疗组的新生血管形成也多于对照组。促红细胞生成素给药10天后未观察到血细胞比容显著升高。
重组人促红细胞生成素通过抑制炎症、减少中性粒细胞浸润、增加一氧化氮以及增强血管生成等可能机制,提高了缺血 - 再灌注损伤大鼠TRAM瓣的皮瓣存活率。